Antileukemic Activity and Tolerability of ASP2215 80mg and Greater in FLT3 Mutation-Positive Subjects with Relapsed or Refractory Acute Myeloid Leukemia: Results from a Phase 1/2, Open-Label, Dose-Escalation/Dose-Response Study
Jessica K. Altman(Northwestern University), Erkut Bahceci(Astellas Pharma (United States)), Jörge E. Cortes(Augusta University Health), Robert K. Stuart(Memorial Sloan Kettering Cancer Center), Raoul Tibes(BioNTech (Germany)), Briana Sargent(Astellas Pharma (United States)), Christoph Röllig(University Hospital Carl Gustav Carus), Stephen A. Strickland(Vanderbilt University), Claudia D. Baldus(University Hospital Schleswig-Holstein), Gary J. Schiller(Fred Hutch Cancer Center), Alexander E. Perl(University of Pennsylvania), Eunice S. Wang(Roswell Park Comprehensive Cancer Center), Alexander I. Spira(Virginia Cancer Specialists), Andreas Neubauer(RWTH Aachen University), Maria R. Baer(University of Maryland, Baltimore), Harry P. Erba(Michigan Center for Translational Pathology), Joseph G. Jurcic(Memorial Sloan Kettering Cancer Center), Celalettin Üstün(Rush University Medical Center), Richard A. Larson(Urbana University), Giovanni Martinelli(University of Bologna), Stanley C. Gill(Nivalis Therapeutics (United States)), Ellen K. Ritchie(Cornell University), Mark R. Litzow(Mayo Clinic in Arizona), Mark J. Levis(Sidney Kimmel Cancer Center), Catherine C. Smith(University of California, San Francisco), David F. Claxton(The University of Texas MD Anderson Cancer Center), Stuart L. Goldberg(Center for Discovery), Charles Y. Lui(University of Arizona)
Cited by 29
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k